Biogen warns of $34M pre-tax IPR&D and upfront charge in Q1 2026, impacting EPS by $0.19

BIOGEN INC.

Preliminary estimate: ~$34M pre-tax acquired in-process R&D, upfront and milestone expense for Q1 2026.
Expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.19 per share.
Expense includes upfront/milestone payments and premiums on equity securities related to collaboration and license agreements.
Biogen does not forecast such costs due to uncertainty; final Q1 results not yet finalized and may differ.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

BIOGEN INC. reported preliminary financial results for the first quarter of 2026.

Period: the first quarter of 2026
Result: preliminary results

Exact text from the filing

Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0000875045-26-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.